Drugmakers like Eli Lilly and Co. plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
The new sites are located at health centers in Johnson, Allen, Vigo, Monroe and Tippecanoe counties, the Indiana Family and Social Services Administration announced Wednesday morning.
Noblesville-based Pharmakon had a history of making state and local incentive agreements before suspending operations last year after a Food and Drug Administration investigation uncovered safety issues and possible criminal activity.
The co-owner of a pharmacy responsible for the deaths of 76 people was sentenced Monday to nine years in prison. Indiana was one of the state hit hardest by the 2012 nationwide fungal meningitis outbreak.
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
While making opioid prescriptions harder to get, Indiana’s crackdown helped spur a twofold increase in robberies of pharmacies that exacerbated the state’s standing as No. 1 in the nation for those crimes.
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
The owner and the director of compliance for Noblesville-based Pharmakon Pharmaceuticals Inc. have been charged with multiple criminal counts related to the sale of over-potent compounded painkillers that sickened at least three infants.
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
In statehouses across the country and in Congress, drugmaker Alkermes is pushing its own addiction treatment while contributing to misconceptions and stigma about other medications used to treat opioid addiction.
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
Besides contributing to overdoses, abuse of Opana ER was blamed for a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles, according to the FDA.
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
After several years in which the value of its assets swelled, philanthropic giant Lilly Endowment Inc. watched its coffers shrink 12.7 percent in 2016 from about $11.8 billion to $10.3 billion.
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
The struggling grocery chain told employees Friday morning that it plans to discontinue pharmacy operations and has sold customer prescription files to a national drug store chain.
